NCT06756308 - A Study of Enasidenib in People With T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 24, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

T-cell Lymphoma

Interventions

DRUG

Enasidenib

Enasidenib 100 mg daily on 28-day cycles.

DRUG

Rituximab

IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab.

Trial Locations (8)

RECRUITING

Memorial Sloan Kettering Westchester (All protocol activities), Harrison

RECRUITING

Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack

NOT_YET_RECRUITING

Dana Farber Cancer Institute (Data Collection Only), Boston

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

RECRUITING

Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge

RECRUITING

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale